{"transactions":[{"id":738199,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-06-15T20:09:46.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":false,"shares":5034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":10068,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5034},"source":{"system":"sec-edgar","filing":"0001159036-26-000077","document":"wk-form4_1781554184.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000077/wk-form4_1781554184.xml","form_type":"4"}},{"id":738198,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-15T20:09:46.000Z","date":"2026-06-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":2715,"price":69.5,"value":188692.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":49929,"source":{"system":"sec-edgar","filing":"0001159036-26-000077","document":"wk-form4_1781554184.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000077/wk-form4_1781554184.xml","form_type":"4"}},{"id":738197,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-15T20:09:46.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":true,"shares":5034,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52644,"source":{"system":"sec-edgar","filing":"0001159036-26-000077","document":"wk-form4_1781554184.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000077/wk-form4_1781554184.xml","form_type":"4"}},{"id":885567,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-02-24T23:16:08.000Z","date":"2026-02-23","kind":"exercise","planned":false,"acquired":false,"shares":7011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":14022,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7011},"source":{"system":"sec-edgar","filing":"0001159036-26-000030","document":"wk-form4_1771974966.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000030/wk-form4_1771974966.xml","form_type":"4"}},{"id":885566,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-02-24T23:16:08.000Z","date":"2026-02-20","kind":"exercise","planned":false,"acquired":false,"shares":5332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15995,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5332},"source":{"system":"sec-edgar","filing":"0001159036-26-000030","document":"wk-form4_1771974966.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000030/wk-form4_1771974966.xml","form_type":"4"}},{"id":885565,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:16:08.000Z","date":"2026-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":3782,"price":70.64,"value":267160.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 3,782 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":47610,"source":{"system":"sec-edgar","filing":"0001159036-26-000030","document":"wk-form4_1771974966.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000030/wk-form4_1771974966.xml","form_type":"4"}},{"id":885564,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:16:08.000Z","date":"2026-02-23","kind":"exercise","planned":false,"acquired":true,"shares":7011,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51392,"source":{"system":"sec-edgar","filing":"0001159036-26-000030","document":"wk-form4_1771974966.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000030/wk-form4_1771974966.xml","form_type":"4"}},{"id":885563,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:16:08.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":2876,"price":70.98,"value":204138.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":44381,"source":{"system":"sec-edgar","filing":"0001159036-26-000030","document":"wk-form4_1771974966.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000030/wk-form4_1771974966.xml","form_type":"4"}},{"id":885562,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:16:08.000Z","date":"2026-02-20","kind":"exercise","planned":false,"acquired":true,"shares":5332,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47257,"source":{"system":"sec-edgar","filing":"0001159036-26-000030","document":"wk-form4_1771974966.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000030/wk-form4_1771974966.xml","form_type":"4"}},{"id":901676,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-17T23:53:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":12016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":12016},"source":{"system":"sec-edgar","filing":"0001159036-26-000027","document":"wk-form4_1771372424.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000027/wk-form4_1771372424.xml","form_type":"4"}},{"id":901675,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T23:53:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":4796,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4796},"source":{"system":"sec-edgar","filing":"0001159036-26-000027","document":"wk-form4_1771372424.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000027/wk-form4_1771372424.xml","form_type":"4"}},{"id":901674,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:53:47.000Z","date":"2026-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":6481,"price":79.44,"value":514850.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 6,481 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":41925,"source":{"system":"sec-edgar","filing":"0001159036-26-000027","document":"wk-form4_1771372424.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000027/wk-form4_1771372424.xml","form_type":"4"}},{"id":901673,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:53:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":12016,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48406,"source":{"system":"sec-edgar","filing":"0001159036-26-000027","document":"wk-form4_1771372424.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000027/wk-form4_1771372424.xml","form_type":"4"}},{"id":901672,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:53:47.000Z","date":"2026-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2587,"price":79.44,"value":205511.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,587 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":36390,"source":{"system":"sec-edgar","filing":"0001159036-26-000027","document":"wk-form4_1771372424.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000027/wk-form4_1771372424.xml","form_type":"4"}},{"id":901671,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:53:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":38977,"source":{"system":"sec-edgar","filing":"0001159036-26-000027","document":"wk-form4_1771372424.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000027/wk-form4_1771372424.xml","form_type":"4"}},{"id":910292,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-12T02:20:59.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":29502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":29502,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":29502},"source":{"system":"sec-edgar","filing":"0001159036-26-000016","document":"wk-form4_1770862856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000016/wk-form4_1770862856.xml","form_type":"4"}},{"id":910291,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-12T02:20:59.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":7808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":45127,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7808},"source":{"system":"sec-edgar","filing":"0001159036-26-000016","document":"wk-form4_1770862856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000016/wk-form4_1770862856.xml","form_type":"4"}},{"id":910290,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-12T02:20:59.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":4651,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":12016,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4651},"source":{"system":"sec-edgar","filing":"0001159036-26-000016","document":"wk-form4_1770862856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000016/wk-form4_1770862856.xml","form_type":"4"}},{"id":910289,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-02-12T02:20:59.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":17396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":17396,"derivative":{"exercise_price":0,"exercise_date":"2027-02-09","underlying":"Common Stock","underlying_shares":17396},"source":{"system":"sec-edgar","filing":"0001159036-26-000016","document":"wk-form4_1770862856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000016/wk-form4_1770862856.xml","form_type":"4"}},{"id":910288,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2026-02-12T02:20:59.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":18730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":18730,"derivative":{"exercise_price":80.48,"exercise_date":"2027-02-09","expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":18730},"source":{"system":"sec-edgar","filing":"0001159036-26-000016","document":"wk-form4_1770862856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000016/wk-form4_1770862856.xml","form_type":"4"}},{"id":947550,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T23:55:28.000Z","date":"2026-01-03","kind":"exercise","planned":false,"acquired":false,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7611},"source":{"system":"sec-edgar","filing":"0001159036-26-000005","document":"wk-form4_1767743723.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000005/wk-form4_1767743723.xml","form_type":"4"}},{"id":947549,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-06T23:55:28.000Z","date":"2026-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":4243,"price":70.31,"value":298325.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 4,243 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":34181,"source":{"system":"sec-edgar","filing":"0001159036-26-000005","document":"wk-form4_1767743723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000005/wk-form4_1767743723.xml","form_type":"4"}},{"id":947548,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-06T23:55:28.000Z","date":"2026-01-03","kind":"exercise","planned":false,"acquired":true,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":38424,"source":{"system":"sec-edgar","filing":"0001159036-26-000005","document":"wk-form4_1767743723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000005/wk-form4_1767743723.xml","form_type":"4"}},{"id":1112178,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-06-13T21:33:05.000Z","date":"2025-06-12","kind":"exercise","planned":false,"acquired":false,"shares":5035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15102,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5035},"source":{"system":"sec-edgar","filing":"0001415889-25-017270","document":"form4-06132025_090601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925017270/form4-06132025_090601.xml","form_type":"4"}},{"id":1112177,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-06-13T21:33:05.000Z","date":"2025-06-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":2711,"price":54.54,"value":147857.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,711 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":30813,"source":{"system":"sec-edgar","filing":"0001415889-25-017270","document":"form4-06132025_090601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925017270/form4-06132025_090601.xml","form_type":"4"}},{"id":1112176,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-06-13T21:33:05.000Z","date":"2025-06-12","kind":"exercise","planned":false,"acquired":true,"shares":5035,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33524,"source":{"system":"sec-edgar","filing":"0001415889-25-017270","document":"form4-06132025_090601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925017270/form4-06132025_090601.xml","form_type":"4"}},{"id":1250104,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-24T22:07:14.000Z","date":"2025-02-23","kind":"exercise","planned":false,"acquired":false,"shares":7012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":21033,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7012},"source":{"system":"sec-edgar","filing":"0001415889-25-005306","document":"form4-02242025_100209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005306/form4-02242025_100209.xml","form_type":"4"}},{"id":1250103,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-24T22:07:14.000Z","date":"2025-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":3775,"price":57.75,"value":218006.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 3,775 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":28489,"source":{"system":"sec-edgar","filing":"0001415889-25-005306","document":"form4-02242025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005306/form4-02242025_100209.xml","form_type":"4"}},{"id":1250102,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-24T22:07:14.000Z","date":"2025-02-23","kind":"exercise","planned":false,"acquired":true,"shares":7012,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32264,"source":{"system":"sec-edgar","filing":"0001415889-25-005306","document":"form4-02242025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005306/form4-02242025_100209.xml","form_type":"4"}},{"id":1253554,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T23:50:29.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":21327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":21327,"derivative":{"exercise_price":0,"exercise_date":"2026-02-20","underlying":"Common Stock","underlying_shares":21327},"source":{"system":"sec-edgar","filing":"0001415889-25-005175","document":"form4-02212025_110225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005175/form4-02212025_110225.xml","form_type":"4"}},{"id":1253553,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2025-02-21T23:50:29.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":22603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":22603,"derivative":{"exercise_price":57.44,"exercise_date":"2026-02-20","expiration_date":"2035-02-20","underlying":"Common Stock","underlying_shares":22603},"source":{"system":"sec-edgar","filing":"0001415889-25-005175","document":"form4-02212025_110225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005175/form4-02212025_110225.xml","form_type":"4"}},{"id":1264517,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T23:41:02.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":9592,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4796},"source":{"system":"sec-edgar","filing":"0001415889-25-004508","document":"form4-02182025_110258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004508/form4-02182025_110258.xml","form_type":"4"}},{"id":1264516,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-18T23:41:02.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":17409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":17409},"source":{"system":"sec-edgar","filing":"0001415889-25-004508","document":"form4-02182025_110258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004508/form4-02182025_110258.xml","form_type":"4"}},{"id":1264515,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:41:02.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2582,"price":58.29,"value":150504.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 2,582 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":25252,"source":{"system":"sec-edgar","filing":"0001415889-25-004508","document":"form4-02182025_110258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004508/form4-02182025_110258.xml","form_type":"4"}},{"id":1264514,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:41:02.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27834,"source":{"system":"sec-edgar","filing":"0001415889-25-004508","document":"form4-02182025_110258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004508/form4-02182025_110258.xml","form_type":"4"}},{"id":1264513,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:41:02.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":9373,"price":58.29,"value":546352.17,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 9,373 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":23038,"source":{"system":"sec-edgar","filing":"0001415889-25-004508","document":"form4-02182025_110258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004508/form4-02182025_110258.xml","form_type":"4"}},{"id":1264512,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:41:02.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":17409,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32411,"source":{"system":"sec-edgar","filing":"0001415889-25-004508","document":"form4-02182025_110258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004508/form4-02182025_110258.xml","form_type":"4"}},{"id":1267867,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:11:03.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":30050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":30050,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":30050},"source":{"system":"sec-edgar","filing":"0001415889-25-004240","document":"form4-02142025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004240/form4-02142025_110259.xml","form_type":"4"}},{"id":1267866,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Unit","published_at":"2025-02-14T23:11:03.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":7269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":7269,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7269},"source":{"system":"sec-edgar","filing":"0001415889-25-004240","document":"form4-02142025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004240/form4-02142025_110259.xml","form_type":"4"}},{"id":1267865,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:11:03.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":4698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":7365,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4698},"source":{"system":"sec-edgar","filing":"0001415889-25-004240","document":"form4-02142025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004240/form4-02142025_110259.xml","form_type":"4"}},{"id":1267864,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:11:03.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":6050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2022 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2022 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":17409,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6050},"source":{"system":"sec-edgar","filing":"0001415889-25-004240","document":"form4-02142025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004240/form4-02142025_110259.xml","form_type":"4"}},{"id":1311404,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-01-06T22:12:58.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":7611,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7611},"source":{"system":"sec-edgar","filing":"0001415889-25-000811","document":"form4-01062025_100155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925000811/form4-01062025_100155.xml","form_type":"4"}},{"id":1311403,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-06T22:12:58.000Z","date":"2025-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":4289,"price":47.74,"value":204756.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 4,289 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":15002,"source":{"system":"sec-edgar","filing":"0001415889-25-000811","document":"form4-01062025_100155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925000811/form4-01062025_100155.xml","form_type":"4"}},{"id":1311402,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-06T22:12:58.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19291,"source":{"system":"sec-edgar","filing":"0001415889-25-000811","document":"form4-01062025_100155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925000811/form4-01062025_100155.xml","form_type":"4"}},{"id":1479506,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-06-14T20:17:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":20137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant of restricted stock units reported on this Form 4 was awarded to Mr. Snyder in recognition of his contribution to the recent issuance of a European patent covering the Company's ENHANZE(R) rHuPH20 product that the Company provides to its licensees."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":20137,"derivative":{"exercise_price":0,"exercise_date":"2025-06-12","underlying":"Common Stock","underlying_shares":20137},"source":{"system":"sec-edgar","filing":"0001415889-24-016891","document":"form4-06142024_080629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924016891/form4-06142024_080629.xml","form_type":"4"}},{"id":1616466,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Restricted Stock Units","published_at":"2024-02-27T22:08:32.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":28045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":28045,"derivative":{"exercise_price":0,"exercise_date":"2025-02-23","underlying":"Common Stock","underlying_shares":28045},"source":{"system":"sec-edgar","filing":"0001415889-24-005542","document":"form4-02272024_100212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005542/form4-02272024_100212.xml","form_type":"4"}},{"id":1616465,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-27T22:08:32.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":29064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":29064,"derivative":{"exercise_price":40.56,"exercise_date":"2025-02-23","expiration_date":"2034-02-23","underlying":"Common Stock","underlying_shares":29064},"source":{"system":"sec-edgar","filing":"0001415889-24-005542","document":"form4-02272024_100212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005542/form4-02272024_100212.xml","form_type":"4"}},{"id":1634616,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Restricted Stock Units","published_at":"2024-02-20T23:55:59.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":false,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":14388,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4796},"source":{"system":"sec-edgar","filing":"0001415889-24-004476","document":"form4-02202024_110248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004476/form4-02202024_110248.xml","form_type":"4"}},{"id":1634615,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2024-02-20T23:55:59.000Z","date":"2024-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2577,"price":36.1,"value":93029.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,577 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":11680,"source":{"system":"sec-edgar","filing":"0001415889-24-004476","document":"form4-02202024_110248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004476/form4-02202024_110248.xml","form_type":"4"}},{"id":1634614,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2024-02-20T23:55:59.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":true,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14257,"source":{"system":"sec-edgar","filing":"0001415889-24-004476","document":"form4-02202024_110248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004476/form4-02202024_110248.xml","form_type":"4"}},{"id":1685834,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Restricted Stock Units","published_at":"2024-01-05T21:04:24.000Z","date":"2024-01-03","kind":"exercise","planned":false,"acquired":false,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15222,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7611},"source":{"system":"sec-edgar","filing":"0001415889-24-000768","document":"form4-01052024_090119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924000768/form4-01052024_090119.xml","form_type":"4"}},{"id":1685833,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2024-01-05T21:04:24.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":2957,"price":35.78,"value":105801.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,957 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":9461,"source":{"system":"sec-edgar","filing":"0001415889-24-000768","document":"form4-01052024_090119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924000768/form4-01052024_090119.xml","form_type":"4"}},{"id":1685832,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2024-01-05T21:04:24.000Z","date":"2024-01-03","kind":"exercise","planned":false,"acquired":true,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12418,"source":{"system":"sec-edgar","filing":"0001415889-24-000768","document":"form4-01052024_090119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924000768/form4-01052024_090119.xml","form_type":"4"}},{"id":2004003,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Restricted Stock Units","published_at":"2023-02-22T00:02:39.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":19184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":19184,"derivative":{"exercise_price":0,"exercise_date":"2024-02-16","underlying":"Common Stock","underlying_shares":19184},"source":{"system":"sec-edgar","filing":"0001415889-23-002955","document":"form4-02222023_120223.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002955/form4-02222023_120223.xml","form_type":"4"}},{"id":2004002,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Option to Purchase Common Stock","published_at":"2023-02-22T00:02:39.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":54955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":54955,"derivative":{"exercise_price":49.26,"exercise_date":"2024-02-16","expiration_date":"2033-02-16","underlying":"Common Stock","underlying_shares":54955},"source":{"system":"sec-edgar","filing":"0001415889-23-002955","document":"form4-02222023_120223.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002955/form4-02222023_120223.xml","form_type":"4"}},{"id":2068879,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Restricted Stock Units","published_at":"2023-01-04T23:00:58.000Z","date":"2023-01-03","kind":"exercise","acquired":false,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":22833,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7611},"source":{"system":"sec-edgar","filing":"0001415889-23-000393","document":"form4-01042023_110131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923000393/form4-01042023_110131.xml","form_type":"4"}},{"id":2068878,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2023-01-04T23:00:58.000Z","date":"2023-01-03","kind":"tax_withholding","acquired":false,"shares":2804,"price":55.13,"value":154584.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,804 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":4807,"source":{"system":"sec-edgar","filing":"0001415889-23-000393","document":"form4-01042023_110131.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923000393/form4-01042023_110131.xml","form_type":"4"}},{"id":2068877,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2023-01-04T23:00:58.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7611,"source":{"system":"sec-edgar","filing":"0001415889-23-000393","document":"form4-01042023_110131.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923000393/form4-01042023_110131.xml","form_type":"4"}},{"id":2444780,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2022-01-05T21:13:23.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":30444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This restricted stock unit grant vests one-fourth on such date and then one-fourth on each anniversary thereafter."}],"balance_after":30444,"derivative":{"exercise_price":0,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":30444},"source":{"system":"sec-edgar","filing":"0001179110-22-000243","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022000243/edgar.xml","form_type":"4"}},{"id":2444779,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Option to Purchase Common Stock","published_at":"2022-01-05T21:13:23.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":83142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":83142,"derivative":{"exercise_price":41.06,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":83142},"source":{"system":"sec-edgar","filing":"0001179110-22-000243","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022000243/edgar.xml","form_type":"4"}}]}